Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089430 | 0.81 | ALDH1A1 (0.36) | MEN1KMT2AGAAL3MBTL1MAOB | |
| SCHEMBL6763543 | 0.80 | ALDH1A1 (0.40) | MEN1KMT2AGAAL3MBTL1MAOB | |
| SCHEMBL2086618 | 0.80 | ALDH1A1 (0.40) | MEN1KMT2AGAAL3MBTL1MAOB | |
| SCHEMBL6322991 | 0.79 | MAOB (0.42) | MEN1KMT2AGAAMAOBALKBH1 | |
| SCHEMBL27750738 | 0.78 | MAOB (0.45) | GAAMAOBALKBH1RAB9APARP15 | |
| SCHEMBL27594863 | 0.77 | MAOB (0.47) | GAAL3MBTL1MAOBALKBH1RAB9A | |
| SCHEMBL2087206 | 0.77 | MAOB (0.47) | GAAL3MBTL1MAOBALKBH1RAB9A | |
| SCHEMBL6322990 | 0.76 | MAOB (0.43) | MEN1KMT2AGAAL3MBTL1MAOB | |
| SCHEMBL12934372 | 0.73 | PPARA (0.53) | GAAPTPN1HPGDALDH1A1MAPT | |
| SCHEMBL12934374 | 0.73 | SMN1; SMN2 (0.43) | MAOBPTPN1ALKBH1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4711621-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| EP-1461323-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2004-09-29 | — | — | EP | claimed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | claimed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | claimed |
| US-7851494-B2 | Method for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070265323-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070249719-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-20050256333-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-6916848-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1461323-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | disclosed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MEN1 2137/4885KMT2A 3364/4885GAA 167/4885 |
| US-20070249719-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | MEN1 2137/4885KMT2A 3364/4885GAA 167/4885 |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MEN1 2137/4885KMT2A 3364/4885GAA 167/4885 |
| US-20050256333-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MEN1 2137/4885KMT2A 3364/4885GAA 167/4885 |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MEN1 2137/4885KMT2A 3364/4885GAA 167/4885 |
| US-20070265323-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | MEN1 2137/4885KMT2A 3364/4885GAA 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.